

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	Little Green Pharma Ltd
<b>ACN</b>	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Angus McDougall Caithness
<b>Date of last notice</b>	1 May 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Banquo Consulting Pty Ltd - Mr Caithness is a director  Angus Caithness SMSF Pty Ltd as trustee for the Caithness Superannuation Fund - Mr Caithness is a director of the trustee and beneficiary
<b>Date of change</b>	7 July 2023

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>No. of securities held prior to change</b></p> <p>* differs to balance in the previous interest notice due to an off-market transfer from Banquo Consulting Pty Ltd to Mr Angus Caithness of 3,500,000 shares on 30 June 2023 for no change in total beneficial ownership</p>	<p><u>Direct</u>  5,739,571* Ordinary shares  100,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024</p> <p><u>Indirect</u>  <i>Banquo Consulting Pty Ltd</i>  5,548,000* Ordinary shares  500,000 Class F Performance Rights  500,000 Class G Performance Rights  500,000 Class H Performance Rights  500,000 Class I Performance Rights  500,000 Class J Performance Rights  500,000 Class K Performance Rights  32,000 Share Rights</p> <p><i>Angus Caithness SMSF Pty Ltd as trustee for the Caithness Superannuation Fund</i>  150,000 Ordinary shares  150,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024</p>
<p><b>Class</b></p>	<p>Fully paid ordinary shares</p>
<p><b>Number acquired</b></p>	<p>11,870 Fully paid ordinary shares</p>
<p><b>Number disposed</b></p>	
<p><b>Value/Consideration</b>  Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>Issued in lieu of Director fees as approved by shareholders on 30 August 2022, at a deemed issue price of \$0.25</p>

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	<u>Direct</u> 5,751,441 Ordinary shares 100,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024  <u>Indirect</u> <i>Banquo Consulting Pty Ltd</i> 5,548,000 Ordinary shares 500,000 Class F Performance Rights 500,000 Class G Performance Rights 500,000 Class H Performance Rights 500,000 Class I Performance Rights 500,000 Class J Performance Rights 500,000 Class K Performance Rights 32,000 Share Rights  <i>Angus Caithness SMSF Pty Ltd as trustee for the Caithness Superannuation Fund</i> 150,000 Ordinary shares 150,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of shares in lieu of Director fees approved at annual meeting on 30 August 2022

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	Little Green Pharma Ltd
<b>ACN</b>	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Michael David Lynch-Bell
<b>Date of last notice</b>	1 May 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
<b>Date of change</b>	7 July 2023
<b>No. of securities held prior to change</b>	1,669,991 Ordinary shares 250,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024 140,000 Retention Share Rights
<b>Class</b>	Fully paid ordinary shares
<b>Number acquired</b>	18,459 Fully paid ordinary shares
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Issued in lieu of Director fees as approved by shareholders on 30 August 2022, at a deemed issue price of \$0.237 per share

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	1,688,450 Ordinary shares 250,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024 140,000 Retention Share Rights
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of shares in lieu of Director fees approved at annual meeting on 30 August 2022

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	Little Green Pharma Ltd
<b>ACN</b>	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Neale William Fong
<b>Date of last notice</b>	1 May 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Riverpalm Pty Ltd ATF NW Fong Family Trust - Dr Fong is a director and beneficiary of the trust  Dr Neale Fong ATF Damblock Trust - Dr Fong is a trustee and beneficiary of the trust
<b>Date of change</b>	7 July 2023
<b>No. of securities held prior to change</b>	Riverpalm Pty Ltd <NW Fong Family Trust> 296,154 Ordinary shares  Dr Neale Fong <Damblock Trust> 1,210,324 Ordinary shares 70,000 Retention Share Rights 125,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024
<b>Class</b>	Fully paid ordinary shares
<b>Number acquired</b>	9,251 Fully paid ordinary shares
<b>Number disposed</b>	Nil

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Issued in lieu of Director fees as approved by shareholders on 30 August 2022, at a deemed issue price of \$0.237 per share
<b>No. of securities held after change</b>	Riverpalm Pty Ltd <NW Fong Family Trust> 296,154 Ordinary shares  Dr Neale Fong <Damblock Trust> 1,219,575 Ordinary shares 70,000 Retention Share Rights 125,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of shares in lieu of Director fees approved at annual meeting on 30 August 2022

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.